Announcements
- Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis
- Cabaletta Bio to Participate in Upcoming Investor Conferences in March
- Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis
- Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis
- Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference
- Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update
- Cabaletta Bio Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis
More ▼
Key statistics
On Tuesday, Cabaletta Bio Inc (CABA*:MEX) closed at 302.00, 8.42% above its 52-week low of 278.55, set on Apr 05, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 307.33 |
---|---|
High | 307.33 |
Low | 302.00 |
Bid | 278.55 |
Offer | 302.00 |
Previous close | 178.41 |
Average volume | 0.00 |
---|---|
Shares outstanding | 46.80m |
Free float | 43.29m |
P/E (TTM) | -- |
Market cap | 579.91m USD |
EPS (TTM) | -1.65 USD |
Data delayed at least 20 minutes, as of Apr 09 2024 12:30 BST.
More ▼